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SUMMARY. In this study we developed and evaluated a pharmaceutical care program (PCP) to reduce
modifiable risk factors of chronic complications of type 2 diabetes. Patients who acquired their anti-dia-
betic drugs from a Brazilian community pharmacies chain were invited to participate in the PCP. The re-
cruited patients were monthly interviewed and information about pharmacotherapy, comorbidities, diet,
physical activity, body mass index (BMI), blood pressure (BP), and waist circumference (WC) were ob-
tained. Evaluation of glycemia, glycated hemoglobin A1c (HbA1c), and lipid profile analyses was done af-
ter the first interview and repeated every four months until finish the PCP. The 51 (91.1 %) patients who
completed the PCP (12 months) showed improvement in the nutritional habits, physical activity, pharma-
coterapeutic follow-up, HbA1c, lipid profile, BP, WC, and BMI. Thus, the PCP was applicable to the type
2 diabetic patients improving diabetes education and reducing modifiable risk factors of chronic complica-
tions.
